Flunitrazepam

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Standard practice
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: flunitrazepam · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

GABA-A potentiation likely blunts experience; long-acting sedation; withdrawal seizures if stopped abruptly.

Human data with psilocybin: None known: no published human data with psilocybin
Common practice: Daily use carries withdrawal risk if stopped abruptly. Any change is the prescriber's decision.

Evidence types on this record

PrStandard practice; no psilocybin-specific data

2 listed · counted on reports

Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]
Withdrawal or rebound if stopped abruptly: Stopping suddenly can cause withdrawal or a rebound of symptoms. Any change to the dose is the prescriber’s decision. Sources [2]

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

None linked

No condition named in state rules is linked to this medication.

Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016., p. 72
Taylor DM, Barnes TRE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. Wiley, 2025., Benzodiazepines, z-drugs and gabapentinoids: dependence, withdrawal effects and discontinuation — class: benzodiazepines